Baseline and year 2 (OLE entry) demographic and disease characteristics in the randomised PREMIER study for patients in the adalimumab+methotrexate cohort who achieved LDA at year 2 and enrolled in the OLE study
| Characteristic | MTX non-use n=84 | MTX use n=56 |
| Age, years | 50.0±13.9 | 51.1±16.0 |
| Female, n (%) | 54 (64) | 43 (77) |
| Rheumatoid factor positive, n (%) | 66 (84)* | 49 (88) |
| RA duration, years | 0.8±0.8 | 0.7±0.8 |
| Prior DMARD use, n (%) | 27 (32) | 15 (27) |
| Baseline corticosteroid use, n (%) | 35 (42) | 18 (32) |